Huperzine A (DB04864): A Comprehensive Pharmacological, Clinical, and Regulatory Review

Executive Summary

Huperzine A is a naturally occurring sesquiterpene alkaloid isolated from the club moss Huperzia serrata, a plant with a long history of use in Traditional Chinese Medicine for a variety of ailments.[1] Identified by Chinese scientists in the 1980s, it has emerged as a molecule of significant interest for the treatment of neurodegenerative disorders, most notably Alzheimer's disease (AD). This report provides a comprehensive analysis of its chemical properties, pharmacological mechanisms, clinical evidence, safety profile, and complex global regulatory status.

The primary pharmacological action of Huperzine A is its function as a potent, selective, and reversible inhibitor of the enzyme acetylcholinesterase (AChE).[5] By preventing the breakdown of the neurotransmitter acetylcholine, it enhances cholinergic transmission, a mechanism shared with several approved AD medications. However, a growing body of evidence reveals that its therapeutic potential extends far beyond simple cholinergic enhancement. Huperzine A possesses a multifaceted neuroprotective profile, engaging in a suite of non-cholinergic activities that target the underlying pathology of neurodegeneration. These mechanisms include weak antagonism of N-methyl-D-aspartate (NMDA) receptors to mitigate excitotoxicity, modulation of amyloid precursor protein (APP) processing toward the non-amyloidogenic pathway, potent antioxidant and anti-inflammatory effects, and the regulation of apoptotic pathways and neurotrophic factors.[5] This dual-action profile, addressing both symptoms and potential disease-modifying pathways, distinguishes it from other AChE inhibitors and forms the basis of its sustained research interest.

Clinically, Huperzine A has been the subject of numerous trials, predominantly conducted in China. Systematic reviews and meta-analyses of these trials consistently suggest that Huperzine A provides beneficial effects on cognitive function, activities of daily living, and global clinical status in patients with AD.[8] However, this promising evidence is critically undermined by the generally low methodological quality, small sample sizes, and high risk of bias inherent in much of the existing literature.[8] Consequently, while the data are encouraging, they are insufficient to support definitive conclusions or widespread clinical recommendations in most Western countries.

The safety profile of Huperzine A is characterized by mild-to-moderate cholinergic side effects, such as nausea, vomiting, and bradycardia, which are consistent with its mechanism of action.[14] While it appears to be well-tolerated in short-term use, a significant gap exists regarding its long-term safety. Its pharmacokinetic profile is favorable, showing good oral bioavailability and blood-brain barrier penetration. Notably, human studies indicate that it is primarily excreted unchanged by the kidneys, with minimal metabolism by the hepatic cytochrome P450 system, suggesting a low potential for metabolic drug-drug interactions—a significant advantage for elderly patients often on multiple medications.

The global regulatory landscape for Huperzine A is remarkably fragmented. It has been an approved prescription drug for the treatment of AD in China since 1994.[6] In contrast, in the United States, it occupies a contentious space, marketed as a dietary supplement but with its legal status questioned by the FDA, which has issued warning letters for illegal disease claims while simultaneously granting it an Orphan Drug Designation for a rare form of epilepsy.[14] In the European Union, it is considered an unauthorized "novel food" and is not permitted in supplements [21], while in Australia, it is not listed on the Australian Register of Therapeutic Goods.[23] This regulatory divergence creates significant confusion and raises public health concerns regarding product quality and safety. In conclusion, Huperzine A remains a highly promising neuropharmacological agent, but its transition from an investigational compound to a globally accepted therapeutic hinges on the execution of large-scale, methodologically rigorous clinical trials to definitively establish its efficacy and long-term safety.

Introduction: Profile of a Sesquiterpene Alkaloid

Historical Context and Ethnobotanical Origins

Huperzine A is a bioactive compound with deep roots in traditional medicine, originating from the firmoss Huperzia serrata (synonym Lycopodium serratum), a plant commonly known as Chinese club moss.[1] In Traditional Chinese Medicine (TCM), this plant, referred to as Qian Ceng Ta, has been utilized for centuries to treat a wide spectrum of conditions.[17] Its historical applications include the treatment of swelling, fever, and blood disorders, as well as physical ailments like contusions, strains, and bruises.[2] Beyond these uses, TCM practitioners also employed

Huperzia serrata for more complex conditions, including schizophrenia, demonstrating a long-held belief in its effects on the central nervous system.[6] This extensive ethnobotanical history provided the foundational knowledge that would later guide modern scientific investigation into its active constituents.

Chemical Discovery and Isolation

The transition of Huperzine A from a component of a traditional herbal remedy to a purified, characterized molecule occurred in the latter half of the 20th century. In the 1980s, scientists at the Chinese Academy of Sciences embarked on a systematic investigation of the chemical components of Huperzia serrata, leading to the isolation and identification of Huperzine A.[6] A landmark 1986 publication by Liu et al. formally reported the discovery of this novel alkaloid and, crucially, its potent and selective inhibitory activity against the enzyme acetylcholinesterase (AChE).[6] This finding was a pivotal moment, as it provided a clear biochemical mechanism that could explain the memory-enhancing effects traditionally associated with the plant. In a notable historical footnote, it was later discovered in 1989 that the chemical structure of Huperzine A was identical to that of an alkaloid named "selagine," which had been isolated from a related species,

Lycopodium selago, and reported in 1960, though its potent AChE activity had not been fully appreciated at that time.[27]

Evolution to Investigational Therapeutic

The discovery of Huperzine A's powerful AChE inhibitory action immediately positioned it as a compound of immense interest for modern pharmacology, particularly in the context of the "cholinergic hypothesis" of Alzheimer's disease (AD), which links cognitive decline to a deficit in the neurotransmitter acetylcholine. Its mechanism of action mirrored that of existing and emerging treatments for AD, sparking a wave of preclinical and clinical research.[1] Early studies quickly revealed that Huperzine A possessed several advantageous properties compared to other AChE inhibitors, including better penetration of the blood-brain barrier and a longer duration of action.[5] Furthermore, subsequent research began to uncover a range of neuroprotective effects beyond AChE inhibition, suggesting it could potentially modify the underlying course of neurodegenerative diseases.[1] This combination of potent symptomatic action and potential disease-modifying properties has cemented Huperzine A's status as a significant investigational therapeutic, leading to its approval as a drug in China and its widespread, albeit controversial, availability as a cognitive-enhancing supplement in other parts of the world.

Physicochemical and Structural Characteristics

A precise understanding of the physicochemical and structural properties of Huperzine A is fundamental to comprehending its pharmacological activity, pharmacokinetic behavior, and formulation development.

Definitive Chemical Identification and Nomenclature

To ensure unambiguous identification, Huperzine A is defined by a standardized set of chemical and database identifiers.

• Generic Name: Huperzine A [2]
• DrugBank ID: DB04864 [2]
• CAS Number: 102518-79-6 [1]
• IUPAC Name: (1R,9R,13E)-1-amino-13-ethylidene-11-methyl-6-azatricyclo[7.3.1.02,7]trideca-2(7),3,10-trien-5-one [1]
• Synonyms: The compound is known by numerous synonyms in scientific literature and commercial products, including: (-)-Huperzine A, (−)-huperazine A, (−)-selagine, L-huperzine A, Selagine, HupA, Huperzine-A, Cerebra, and Hyperazzine A.[2]

Structural Analysis and Stereochemistry

The unique three-dimensional structure of Huperzine A is directly responsible for its biological activity.

• Chemical Formula:  [2]
• Molecular Weight: The average molecular weight is 242.3162 g/mol, with a monoisotopic mass of 242.141913208 g/mol.[2]
• Chemical Classifications: Huperzine A is a complex molecule belonging to several chemical classes. It is a sesquiterpene alkaloid, indicating its origin from a 15-carbon terpene precursor and the presence of a nitrogen atom within its structure. It is also classified as a pyridone, a primary amino compound, and an organic heterotricyclic compound.[1] More specifically, it is a Lycopodium alkaloid belonging to the lycodine structural group.[17]
• Stereochemistry and Biological Activity: The biological activity of Huperzine A is highly dependent on its specific stereochemistry. The naturally occurring and pharmacologically active form is the levorotatory isomer, (−)-Huperzine A. The unnatural enantiomer, (+)-Huperzine A, has been shown to be at least 50 times less potent as an inhibitor of acetylcholinesterase.[6] This pronounced difference underscores the stereospecific nature of the binding interaction between the molecule and the active site of the AChE enzyme, where a precise three-dimensional fit is required for potent inhibition.
• Structural Representations: Definitive structural information is captured in standardized chemical notations:
• InChI: InChI=1S/C15H18N2O/c1-3-11-10-6-9(2)8-15(11,16)12-4-5-14(18)17-13(12)7-10/h3-6,10H,7-8,16H2,1-2H3,(H,17,18)/b11-3+/t10-,15+/m0/s1 [1]
• InChIKey: ZRJBHWIHUMBLCN-YQEJDHNASA-N [1]
• SMILES: C/C=C/1\[C@@H]2CC3=C([C@]1(CC(=C2)C)N)C=CC(=O)N3 [1]

Key Physical and Chemical Properties

The physical properties of Huperzine A influence its handling, formulation, and physiological behavior.

• Physical State: It exists as a white to off-white crystalline powder.[26]
• Solubility: Huperzine A is soluble in organic solvents such as dimethyl sulfoxide (DMSO), methanol, and ethanol. Its solubility in water is limited, estimated at 124 mg/L at 25 °C.[28]
• Melting Point: The reported melting point range is 228.0 to 233.0 °C.[26]
• Stability and Storage: The compound is stable for four years or more when stored as a powder at -20°C.[5] It is noted to be sensitive to both air and heat, and for long-term preservation, storage under an inert gas atmosphere is recommended.[26]

The following table consolidates the key identifiers and physicochemical properties of Huperzine A for easy reference.

Property	Value	Source Snippet(s)
DrugBank ID	DB04864	2
CAS Number	102518-79-6	1
IUPAC Name	(1R,9R,13E)-1-amino-13-ethylidene-11-methyl-6-azatricyclo[7.3.1.02,7]trideca-2(7),3,10-trien-5-one	1
Molecular Formula		2
Average Molecular Weight	242.3162 g/mol	2
Physical State	White to off-white powder/crystal	26
Solubility (Water)	124 mg/L @ 25 °C (estimated)	28
Solubility (Organic Solvents)	Soluble in DMSO, methanol, ethanol	30
Melting Point	228.0 - 233.0 °C	26
InChIKey	ZRJBHWIHUMBLCN-YQEJDHNASA-N	1
SMILES	C/C=C/1\[C@@H]2CC3=C([C@]1(CC(=C2)C)N)C=CC(=O)N3	1

Comprehensive Pharmacological Profile

The pharmacological profile of Huperzine A is complex and multifaceted. While its primary, most well-characterized mechanism is the potent inhibition of acetylcholinesterase, a growing body of research has illuminated a range of non-cholinergic, neuroprotective actions that may contribute significantly to its therapeutic effects. This dual-action profile distinguishes it from many other agents in its class.

Primary Mechanism: Potent and Reversible Acetylcholinesterase Inhibition

The cornerstone of Huperzine A's activity is its interaction with acetylcholinesterase (AChE), the enzyme responsible for the hydrolysis and subsequent inactivation of the neurotransmitter acetylcholine (ACh) in the synaptic cleft.[4] By inhibiting AChE, Huperzine A increases the concentration and prolongs the action of ACh at cholinergic synapses, thereby enhancing cholinergic neurotransmission, which is crucial for cognitive processes like learning and memory.[4]

Binding Affinity and Kinetics

Huperzine A is characterized as a potent, highly specific, and reversible inhibitor of AChE.[5] Kinetic studies using Lineweaver-Burk analysis have established that it acts as a competitive inhibitor, meaning it competes with acetylcholine for binding at the enzyme's active site.[6] Its binding affinity is notably high, with a reported inhibition constant (

) of 7 nM and a half-maximal inhibitory concentration () of 82 nM against AChE in rat cortex tissue.[5] The interaction is reversible; upon removal of the inhibitor, the enzyme regains its activity, which is a key safety feature compared to irreversible inhibitors.[6] The precise molecular interactions have been elucidated through X-ray crystallography of the Huperzine A-AChE complex (PDB code: 1VOT), which reveals critical hydrogen bonds and a strong interaction between the protonated amino group of Huperzine A and the aromatic side chains of tryptophan (Trp84) and phenylalanine (Phe330) residues within the active-site gorge of the enzyme.[6]

Selectivity

A key pharmacological advantage of Huperzine A is its high selectivity for AChE over the related enzyme butyrylcholinesterase (BuChE). It exhibits approximately 900-fold greater selectivity for AChE.[6] BuChE is more broadly distributed in the periphery and its inhibition is often associated with undesirable cholinergic side effects. The high selectivity of Huperzine A for AChE may therefore contribute to a more favorable side-effect profile compared to less selective inhibitors, such as tacrine, which has very low selectivity.[6]

Comparative Analysis with Marketed AChE Inhibitors

When evaluated against AChE inhibitors that are approved for the treatment of Alzheimer's disease, Huperzine A demonstrates a unique and compelling profile.

• Potency: In vitro studies show its AChE inhibitory potency is greater than that of tacrine and galantamine but less potent than donepezil.[5] However, this in vitro comparison does not fully capture its clinical potential. When administered orally, Huperzine A is significantly more potent on a molar basis—approximately 24 times more potent than donepezil and 180 times more potent than tacrine.[6]
• Pharmacokinetic Advantages: This superior in vivo potency is attributed to a combination of favorable pharmacokinetic properties. Huperzine A is reported to have greater penetration of the blood-brain barrier, higher oral bioavailability, and a longer duration of AChE inhibition compared to tacrine, donepezil, and rivastigmine.[5] These features allow it to achieve and sustain effective concentrations in the central nervous system at lower oral doses.

The following table provides a comparative summary of Huperzine A and other clinically relevant AChE inhibitors.

Compound	/ (AChE)	Selectivity (AChE/BuChE)	Reversibility	Key Pharmacokinetic Feature	Source Snippet(s)
Huperzine A	= 7 nM;  = 82 nM	~900-fold	Reversible, Competitive	High oral potency, good BBB penetration, long duration of action	5
Donepezil	= 12.5 nM;  = 10 nM	~500-fold	Reversible, Non-competitive	Long plasma half-life	6
Rivastigmine	More potent than HupA in vitro	Lower than HupA	Pseudo-irreversible	Inhibits both AChE and BuChE	5
Galantamine	Less potent than HupA in vitro	Lower than HupA	Reversible, Competitive	Dual mechanism: also modulates nicotinic receptors	5
Tacrine	= 105 nM;  = 93 nM	~0.8-fold (non-selective)	Reversible, Non-competitive	Associated with hepatotoxicity	6

Multifaceted Neuroprotective and Non-Cholinergic Mechanisms

While AChE inhibition explains the symptomatic cognitive benefits of Huperzine A, its full therapeutic potential appears to stem from a synergistic combination of this primary action with a diverse array of non-cholinergic, neuroprotective mechanisms. The initial focus on AChE inhibition mirrored the development pathway of other AD drugs, providing a clear, symptomatic target. However, extensive research has revealed that Huperzine A also directly intervenes in several core pathological processes of neurodegeneration, such as excitotoxicity, amyloid plaque formation, oxidative stress, and apoptosis. This suggests that Huperzine A is not merely a symptomatic treatment but may possess disease-modifying properties. This multifaceted profile, which simultaneously addresses the cholinergic deficit and the underlying neurodegenerative cascade, likely accounts for the sustained scientific interest in the compound as a potentially superior therapeutic agent.

Detailed Mechanisms

• NMDA Receptor Antagonism: Huperzine A functions as a weak antagonist at the N-methyl-D-aspartate (NMDA) receptor.[5] Over-activation of NMDA receptors by the neurotransmitter glutamate leads to excessive calcium influx and subsequent neuronal damage, a process known as excitotoxicity, which is a key contributor to neuronal death in AD.[7] By weakly blocking these receptors, Huperzine A can help protect neurons from this glutamate-induced damage.[7] While its affinity for the NMDA receptor is relatively low (  ~65–82 µM), this action may still provide a clinically relevant neuroprotective effect at therapeutic concentrations, complementing its primary cholinergic activity.[27]
• Modulation of Amyloid Precursor Protein (APP) Processing: One of the most significant non-cholinergic effects of Huperzine A is its ability to influence the metabolic processing of the amyloid precursor protein (APP), a central element in AD pathology. It promotes the non-amyloidogenic processing pathway by enhancing the activity of α-secretase.[6] This enzymatic cleavage occurs within the β-amyloid (Aβ) sequence, thereby precluding the formation of the toxic Aβ peptide and instead generating soluble, neuroprotective α-APP fragments (sAPPα).[6] This effect is mediated through the activation of M1 muscarinic acetylcholine receptors, which in turn stimulates protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) signaling pathways that regulate α-secretase activity.[33] By shifting APP metabolism away from the production of toxic Aβ, Huperzine A directly targets a fundamental cause of neuronal dysfunction and death in AD.
• Antioxidant and Anti-inflammatory Properties: Huperzine A exhibits robust antioxidant activity, protecting cells from oxidative stress, which is another major contributor to neurodegeneration.[7] It has been shown to protect neurons against damage induced by agents like hydrogen peroxide and Aβ peptide.[5] This protection is achieved through multiple actions: directly scavenging harmful free radicals and enhancing the body's own antioxidant defense systems by increasing the activity of enzymes such as superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and catalase (CAT).[7] Additionally, it possesses anti-inflammatory properties, further helping to quell the chronic neuroinflammation associated with AD.[12]
• Regulation of Apoptotic Pathways: Apoptosis, or programmed cell death, is the final common pathway for neuronal loss in AD. Huperzine A has demonstrated significant anti-apoptotic effects. It modulates the expression of key regulatory proteins in the apoptotic cascade, upregulating the anti-apoptotic protein Bcl-2 while downregulating the pro-apoptotic proteins Bax and p53.[5] Furthermore, it inhibits the activation of caspase-3 and caspase-9, critical executioner enzymes in the apoptotic process, thereby directly interfering with the cellular machinery of cell death.[5]
• Neurotrophic Factor Regulation: The compound supports neuronal health and survival by promoting the expression of neurotrophic factors. Studies have shown that Huperzine A can upregulate the production of nerve growth factor (NGF) and its corresponding receptors.[5] NGF is vital for the growth, maintenance, and survival of cholinergic neurons, which are particularly vulnerable in AD, making this another important neuroprotective mechanism.[32]
• Mitochondrial Protection: Mitochondrial dysfunction is a hallmark of neurodegenerative diseases, leading to energy failure and increased production of damaging reactive oxygen species (ROS). Huperzine A has been shown to protect and improve mitochondrial function.[7] By enhancing the efficiency of mitochondria, it helps to maintain cellular energy production (ATP synthesis) and reduces the generation of ROS, thus mitigating a primary source of oxidative stress and cellular damage.[7]

Pharmacokinetic and Metabolic Profile

The pharmacokinetic profile of Huperzine A, encompassing its absorption, distribution, metabolism, and excretion (ADME), is crucial for understanding its clinical efficacy, dosing regimen, and potential for drug interactions. The data reveal a compound with favorable characteristics for a centrally-acting agent but also highlight complexities that require careful consideration, particularly regarding its use in elderly populations.

Absorption, Bioavailability, and Distribution

Following oral administration, Huperzine A is absorbed rapidly, with quantifiable levels appearing in the plasma within 5 to 15 minutes.[39] Peak plasma concentrations (

) are typically reached within approximately 60 to 80 minutes, indicating swift uptake from the gastrointestinal tract.[39]

A key advantage of Huperzine A is its ability to effectively cross the blood-brain barrier (BBB).[5] This property is essential for its therapeutic action, as its primary targets, including acetylcholinesterase and NMDA receptors, are located within the central nervous system (CNS). This efficient CNS penetration, combined with reports of high oral bioavailability, contributes to its superior in vivo potency compared to other AChE inhibitors.[5] Pharmacokinetic modeling indicates that Huperzine A is widely distributed throughout the body, with a large apparent volume of distribution (

) of approximately 104 L, confirming that it does not remain confined to the bloodstream but partitions extensively into tissues, including the brain.[39]

Metabolism: Elucidating the Role of Cytochrome P450 Enzymes and Renal Excretion

The metabolic fate of Huperzine A is a critical determinant of its drug-drug interaction (DDI) profile. Analysis of available data reveals a significant finding: in humans, Huperzine A largely bypasses hepatic metabolism via the cytochrome P450 (CYP) enzyme system, with renal excretion of the parent drug being the predominant elimination pathway. This contrasts with many other small molecule drugs and has important clinical implications.

Initial in vitro studies using rat liver microsomes suggested that Huperzine A metabolism was mediated primarily by CYP1A2, with a secondary contribution from CYP3A1/2.[41] However, this finding in an animal model does not accurately reflect the human situation. A more clinically relevant study utilizing human liver microsomes and human hepatocytes provided a different conclusion. In this human-derived system, Huperzine A was not significantly metabolized over a 90-minute incubation period and, importantly, showed negligible inhibitory or inductive effects on a panel of major human CYP isoforms (including CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4) at clinically relevant concentrations.[42]

This in vitro finding is strongly supported by in vivo data from a pharmacokinetic study in elderly human subjects. In this study, a substantial portion of the administered oral dose—approximately 35%—was recovered in the urine as unchanged Huperzine A within 48 hours.[42] The combination of minimal in vitro metabolism and significant renal excretion of the parent drug strongly indicates that hepatic metabolism is not the primary clearance mechanism in humans. This low reliance on the CYP450 system means that Huperzine A has a low intrinsic potential for causing metabolic drug-drug interactions. This is a considerable advantage, particularly for the target AD patient population, who are typically elderly and often take multiple concurrent medications (polypharmacy), reducing the risk of altered drug efficacy or toxicity from enzyme inhibition or induction.

Elimination Dynamics: Analysis of Reported Half-Life Discrepancies and Pharmacokinetic Modeling

The elimination of Huperzine A from the body is complex, with studies reporting a range of half-life values and fitting the data to different pharmacokinetic models. This variability appears to be influenced by the study population and the analytical approach used, highlighting the need for careful dose consideration.

Several different elimination half-life values have been reported in the literature, including approximately 4.8 hours (288 minutes) [17], a range of 10–14 hours [27], and a terminal elimination half-life (

) of about 12 hours (716 minutes).[39] The source of these discrepancies can be understood by examining the underlying studies.

The ~12-hour terminal half-life was determined in a study of young, healthy volunteers (aged 20–25). In this population, the plasma concentration-time profile was best described by a two-compartment open model. This model is characterized by a biphasic decline: an initial, rapid distribution phase (with a half-life, , of ~21 minutes) where the drug moves from the central compartment (blood) into peripheral tissues, followed by a slower, terminal elimination phase ( of ~12 hours) which reflects the clearance of the drug from the body.[39]

In contrast, a population pharmacokinetic (PPK) analysis conducted in a cohort of elderly Chinese individuals found that the data were better described by a simpler one-compartment model.[39] This study yielded a crucial finding: age was identified as a significant covariate that influences the clearance of Huperzine A. Specifically, as age increases, the clearance of the drug decreases.[39]

This age-dependent clearance provides a logical explanation for the different pharmacokinetic models and half-life values. In elderly patients, the slower clearance may make the initial rapid distribution phase less distinct, causing the overall elimination profile to appear more like a one-compartment model. The slower clearance in the elderly, the primary target population for AD therapy, means that they are likely to have higher overall drug exposure (Area Under the Curve, or AUC) and a longer effective half-life compared to younger individuals for a given dose. This has direct clinical implications, as it increases the potential for drug accumulation and the risk of dose-dependent cholinergic side effects. This underscores the importance of careful dose titration in older adults and provides a strong rationale for the development of alternative formulations, such as controlled-release tablets, which can provide more stable plasma concentrations and potentially improve the safety and tolerability of the drug.[18]

Critical Review of Clinical Efficacy

The clinical development of Huperzine A has primarily focused on its potential to treat cognitive deficits in neurodegenerative disorders, with the vast majority of research centered on Alzheimer's disease. While numerous studies have been conducted, a critical appraisal of the evidence reveals a pattern of promising but ultimately inconclusive results, largely due to methodological limitations in the available trials.

Alzheimer's Disease: A Synthesis of Clinical Evidence

The body of clinical evidence for Huperzine A in Alzheimer's disease (AD) consists of individual randomized controlled trials (RCTs) and a larger number of systematic reviews and meta-analyses that aggregate data from these trials.

Analysis of Key Trials

One of the most significant trials conducted outside of China was a US-based, multicenter, Phase II study (NCT00083590) designed to assess the safety and efficacy of Huperzine A in patients with mild to moderate AD.[11] This trial randomized 210 participants to receive either placebo, Huperzine A 200 µg twice daily (BID), or Huperzine A 400 µg BID for 16 weeks. The primary endpoint was the change in the Alzheimer's Disease Assessment Scale–cognitive subscale (ADAS-Cog) score at week 16 for the 200 µg BID dose. The study failed to meet its primary endpoint, showing no statistically significant cognitive benefit with the 200 µg BID dose compared to placebo.[11] However, in a secondary analysis, the higher dose of 400 µg BID demonstrated a statistically significant improvement of 2.27 points on the ADAS-Cog at an earlier time point (week 11) compared to a 0.29-point decline in the placebo group. By week 16, this effect was no longer statistically significant (

), suggesting a potential but possibly transient benefit at the higher dose.[11] No significant effects were observed on global impression of change, activities of daily living, or neuropsychiatric symptoms at either dose.[11] Despite these mixed results, research interest continues, as evidenced by ongoing or recently planned Phase II/III trials in China evaluating novel controlled-release tablet formulations of Huperzine A (e.g., NCT07066826).[48]

Systematic Reviews and Meta-Analyses

A substantial portion of the evidence for Huperzine A's efficacy comes from the aggregation of smaller trials, most of which were conducted in China. Several systematic reviews and meta-analyses have been published, and they collectively paint a consistent picture.

• Positive Findings: These reviews generally conclude that Huperzine A appears to have beneficial effects on the key domains affected by AD. Compared with placebo, treatment with Huperzine A was associated with statistically significant improvements in cognitive function, as measured by scales such as the Mini-Mental State Examination (MMSE), the Hasegawa Dementia Scale (HDS), and the Wechsler Memory Scale (WMS).[8] The benefits extended beyond cognition to functional abilities, with improvements noted in Activities of Daily Living (ADL) scores.[8] Some analyses also found improvements in global clinical assessment, as measured by the Clinical Dementia Rating (CDR) scale, and suggested that longer treatment durations (e.g., 12–24 weeks) might lead to greater efficacy.[9]
• Critical Appraisal and Caveats: Despite these positive statistical findings, every major systematic review includes a critical and significant caveat: the evidence base is weak. The included trials are consistently flagged for being of poor methodological quality and carrying a high risk of bias.[8] Common limitations include small sample sizes, inadequate or unclear methods of randomization and allocation concealment, lack of double-blinding, and a high potential for publication bias, where trials with positive results are more likely to be published than those with negative or null findings.[8] This systematic weakness in the primary data means that while the results are promising and warrant further investigation, they are not robust enough to form the basis for firm clinical recommendations in most evidence-based guidelines.[12] The overall quality of the evidence is consistently rated as "low" or "very low."

The following table summarizes the findings from key clinical evidence sources, highlighting both the reported outcomes and the critical limitations.

Study/Identifier	Phase/Type	Population	N	Dosage	Duration	Key Outcomes (Cognitive, Functional)	Summary of Results	Noted Limitations/Risk of Bias	Source Snippet(s)
NCT00083590	Phase II RCT	Mild-to-moderate AD	210	200 µg BID or 400 µg BID	16 weeks	ADAS-Cog, ADCS-CGIC, ADCS-ADL	Primary endpoint (200 µg) not met. Secondary analysis showed transient cognitive benefit at 400 µg (week 11), but not significant at week 16. No effect on global or functional measures.	Provides Class III evidence of no demonstrable effect at 200 µg BID.	11
Yang et al., 2013	Meta-analysis of RCTs	AD	1823 (20 RCTs)	Varied	8-24 weeks	MMSE, HDS, WMS, ADL, CDR	Significant beneficial effects on cognitive function (MMSE, HDS, WMS), daily living activity (ADL), and global assessment (CDR) compared to placebo.	"Poor methodological quality of the included trials." Findings should be "interpreted with caution."	8
Wang et al., 2009	Meta-analysis of RCTs	AD	4 RCTs	300-500 µg daily	8-24 weeks	MMSE, ADL	Significant improvements in both MMSE and ADL scores. Effect size increased with treatment duration.	Limited number of trials included.	9
Li et al., 2008 (Cochrane Review)	Systematic Review of RCTs	AD	454 (6 RCTs)	Varied	8-12 weeks	MMSE, ADL	Huperzine A seemed to have beneficial effects on cognitive function and ADL.	"Insufficient evidence to make any recommendation" due to small sample sizes and poor methodological quality of included trials.	25
Ghassab-Abdollahi et al., 2021	Overview of Systematic Reviews	Dementia & MCI	-	Varied	Varied	Cognitive function, ADL	Beneficial effects on cognition and ADLs in AD. Insufficient evidence for vascular dementia or MCI.	"Insufficient evidence to support effectiveness" due to high heterogeneity of reviews and low quality of primary studies.	12

Investigational Use in Other Conditions

Beyond Alzheimer's disease, the unique pharmacological profile of Huperzine A has prompted investigation into its utility for a range of other conditions.

• Vascular Dementia (VD): As the second most common form of dementia, VD has been a logical target for Huperzine A. Some research suggests that it may improve both cognitive function and activities of daily living in patients with VD, and one meta-analysis indicated that it might produce fewer side effects in this population compared to AD patients.[20] However, the overall evidence is considered mixed and insufficient to draw firm conclusions.[12]
• Age-Related Cognitive Impairment: Huperzine A has been studied for less severe forms of cognitive decline. Early research in adults with mild cognitive impairment (MCI) suggested a potential for memory improvement after 12 weeks of treatment.[15] Another small study in adolescents complaining of memory problems reported improved memory scores after 4 weeks of use.[15] However, this evidence is preliminary and insufficient for clinical recommendations.[15]
• Myasthenia Gravis: This autoimmune disorder is characterized by muscle weakness due to impaired cholinergic transmission at the neuromuscular junction. Early research explored the use of intramuscular Huperzine A to prevent muscle weakness, with findings suggesting its effects were comparable to or longer-lasting than the standard agent, neostigmine.[15]
• Organophosphate Poisoning: Organophosphate nerve agents (e.g., soman, sarin) exert their toxicity by irreversibly inhibiting AChE. Huperzine A's potent, reversible AChE inhibition and its ability to cross the BBB make it a promising candidate for prophylactic treatment. By temporarily occupying the AChE enzyme, it can protect it from irreversible phosphorylation by the nerve agent. Animal studies have shown it to be effective in preventing lethality and neurological damage from organophosphate exposure, demonstrating superior protection compared to peripherally-acting agents like pyridostigmine.[6]
• Cocaine Dependence: A Phase 1 clinical trial (NCT01030692) investigated Huperzine A as a potential treatment for cocaine dependence.[53] Given the complex interplay of neurotransmitter systems in addiction, the rationale involves modulating cholinergic and other pathways. One report from this research indicated that a 0.4 mg dose of Huperzine A significantly attenuated some of the subjective rewarding effects of cocaine, such as "High" and "Willing to Pay".[54]
• Cognitive Enhancement in Healthy Populations: Despite being widely marketed as a nootropic or cognitive enhancer for healthy individuals, there is a lack of robust scientific evidence to support these claims. A randomized, double-blind, crossover trial in exercise-trained individuals found that acute consumption of Huperzine A did not enhance cognitive function during exercise and, in fact, increased the subjective perception of difficulty.[55] While one small trial in Chinese junior high students suggested some memory improvement, the clinical significance of the finding was unclear and has not been replicated in larger, more rigorous studies.[13]

Safety, Tolerability, and Risk Assessment

The safety and tolerability profile of Huperzine A is a critical consideration for its potential therapeutic use. The available data, primarily from short-term clinical trials, indicate a generally manageable side-effect profile dominated by cholinergic effects, but also highlight important precautions and a significant lack of long-term safety information.

Adverse Effect Profile

The most commonly reported adverse effects of Huperzine A are a direct consequence of its primary mechanism of action—the inhibition of acetylcholinesterase, which leads to increased cholinergic activity throughout the body. These effects are typically rated as mild to moderate in severity.[27]

Commonly reported adverse events include [14]:

• Gastrointestinal: Nausea, vomiting, diarrhea, abdominal cramps, increased salivation.
• Cardiovascular: Bradycardia (slowed heart rate), high blood pressure.
• Neurological: Dizziness, headache, restlessness, insomnia.
• Musculoskeletal: Muscle cramping, twitching of muscle fibers.
• Other: Increased sweating, blurred vision, slurred speech.

Interestingly, one study in mice observed that while a single dose of Huperzine A significantly increased gastrointestinal motility (consistent with cholinergic side effects), this effect was not observed after multiple daily doses (7 or 28 days). This suggests that tolerance may develop to the peripheral gastrointestinal side effects over time, potentially improving long-term tolerability.[57]

Contraindications, Warnings, and Precautions

Due to its cholinomimetic effects, Huperzine A should be used with caution, or avoided entirely, in individuals with certain pre-existing medical conditions that could be exacerbated by increased cholinergic tone.[15]

• High-Risk Populations:
• Cardiovascular Conditions: Individuals with bradycardia or other heart rhythm disturbances should use Huperzine A cautiously, as it can further slow the heart rate.[15]
• Neurological Conditions: There is a theoretical concern that by altering brain chemistry, Huperzine A could lower the seizure threshold or worsen epilepsy. Caution is advised for patients with a history of seizure disorders.[15]
• Gastrointestinal Conditions: Because it can increase mucous and fluid secretions in the gut, it may worsen conditions like gastrointestinal (GI) tract blockage or peptic ulcers.[15]
• Respiratory Conditions: Increased secretions in the lungs could potentially exacerbate conditions such as asthma or chronic obstructive pulmonary disease (COPD).[15]
• Genitourinary Conditions: There is a concern that it could worsen urinary tract or reproductive system blockages by increasing fluid secretions.[15]
• Pregnancy and Lactation: There is insufficient reliable information on the safety of Huperzine A during pregnancy or breastfeeding. Therefore, its use in these populations is not recommended.[15]

Analysis of Drug-Drug Interactions

The potential for drug-drug interactions (DDIs) with Huperzine A is primarily pharmacodynamic in nature, rather than metabolic. As established in the pharmacokinetics section, Huperzine A undergoes minimal metabolism by the hepatic CYP450 enzyme system in humans, which significantly lowers the risk of metabolic DDIs.[42] However, its potent effect on the cholinergic system creates a predictable and clinically significant risk of pharmacodynamic interactions when co-administered with other drugs that modulate cholinergic pathways or affect heart rate.

The interaction profile can be logically deduced from its mechanism. As a potent AChE inhibitor, Huperzine A will have additive or synergistic effects with other drugs that increase cholinergic activity and antagonistic effects with drugs that block it. This is confirmed by numerous drug interaction databases and clinical advisories.

• Additive Cholinergic Effects: Co-administration with other acetylcholinesterase inhibitors (e.g., donepezil, rivastigmine, galantamine) or direct-acting cholinergic agonists (e.g., bethanechol, cevimeline, pilocarpine) can lead to an overstimulation of the cholinergic system. This significantly increases the risk and severity of adverse effects such as nausea, vomiting, diarrhea, bradycardia, and muscle cramps.[2]
• Antagonistic Effects: Conversely, the therapeutic efficacy of Huperzine A can be diminished by co-administration with anticholinergic drugs. These drugs, which block acetylcholine receptors, work in direct opposition to Huperzine A's mechanism. This class includes medications like atropine, scopolamine, diphenhydramine (an antihistamine), and many tricyclic antidepressants and antipsychotics. Taking these drugs concurrently can reduce the cognitive benefits of Huperzine A, and likewise, Huperzine A can reduce the intended effects of the anticholinergic medication.[2]
• Additive Bradycardic Effects: Due to its potential to slow the heart rate, Huperzine A can have an additive effect with other drugs that also cause bradycardia. This is particularly relevant for beta-adrenergic blockers (e.g., acebutolol, carvedilol, propranolol), which are commonly prescribed for cardiovascular conditions in the elderly population. The combination may lead to an unsafe drop in heart rate.[2]

The following table categorizes the most clinically significant pharmacodynamic drug-drug interactions with Huperzine A.

Interacting Drug Class	Specific Examples	Mechanism of Interaction (Pharmacodynamic)	Potential Clinical Outcome	Source Snippet(s)
Acetylcholinesterase Inhibitors	Donepezil, Rivastigmine, Galantamine, Tacrine, Neostigmine	Synergism: Both inhibit AChE, leading to excessive ACh levels.	Increased risk and severity of cholinergic side effects (nausea, vomiting, diarrhea, bradycardia).	15
Cholinergic Agonists	Bethanechol, Carbamoylcholine, Cevimeline, Pilocarpine	Synergism: Huperzine A prevents ACh breakdown while agonist directly stimulates ACh receptors.	Increased risk of cholinergic overstimulation and adverse effects.	2
Anticholinergic Agents	Atropine, Scopolamine, Diphenhydramine, Benztropine, Oxybutynin, Tricyclic Antidepressants	Antagonism: Huperzine A increases ACh levels while these drugs block ACh receptors.	Decreased therapeutic efficacy of both Huperzine A and the anticholinergic drug.	2
Beta-Adrenergic Blockers	Acebutolol, Alprenolol, Betaxolol, Carvedilol, Bisoprolol	Synergism: Both agents can slow the heart rate (bradycardia).	Increased risk of excessive bradycardia, dizziness, and syncope.	2
Neuromuscular Blocking Agents	Atracurium, Cisatracurium, Doxacurium (non-depolarizing agents)	Antagonism: Increased ACh at the neuromuscular junction counteracts the block.	Decreased therapeutic efficacy of the neuromuscular blocker.	2

Toxicology and Long-Term Safety

Preclinical toxicology studies in animal models suggest that Huperzine A has a wide margin of safety. No significant toxicity was observed even when administered at doses 50 to 100 times the human therapeutic dose.[27] However, a critical and repeatedly emphasized gap in the knowledge base is the absence of robust, long-term safety data in humans. The vast majority of clinical trials have been of short duration, typically 36 weeks or less.[13] This lack of chronic use data makes it difficult to assess the risks associated with the long-term administration that would be required for treating a chronic condition like Alzheimer's disease.[13]

Global Regulatory Landscape and Market Status

The legal and market status of Huperzine A is characterized by significant global fragmentation. The same molecule is treated as a prescription drug, a contentious dietary supplement, or an unauthorized substance depending on the jurisdiction. This regulatory divergence creates confusion for patients and healthcare providers, poses challenges for global pharmaceutical development, and raises substantial public health concerns related to product quality and safety, particularly in markets where it is sold with minimal oversight.

This disparate regulatory treatment stems from differing national frameworks for drugs, traditional medicines, and dietary supplements. In China, its long history in TCM and the extensive local research base facilitated its approval as a conventional drug. In the US, it entered the market under the framework of the Dietary Supplement Health and Education Act (DSHEA), which has less stringent pre-market approval requirements than for pharmaceuticals. In Europe, a stricter approach to novel food ingredients has effectively blocked its sale as a supplement. This situation has created a "gray market" where product quality can be highly variable and sometimes dangerous. Studies analyzing commercially available Huperzine A supplements have found that the actual content often deviates significantly from the labeled amount and that some products are adulterated with undeclared and potentially harmful synthetic stimulants.[14]

• China: Huperzine A has the most established regulatory status in China. It was approved by the National Medical Products Administration (NMPA) as a prescription drug for the treatment of Alzheimer's disease in 1994.[6] It is widely available in Chinese hospitals and is a standard part of the therapeutic armamentarium for dementia. There is also ongoing pharmaceutical development within China to create improved formulations, such as fast/controlled biphasic release tablets, which have been approved for clinical trials by the NMPA with the aim of improving patient compliance and reducing side effects.[44]
• United States: The status of Huperzine A in the US is highly ambiguous and paradoxical. It is widely marketed and sold as an over-the-counter dietary supplement, primarily for cognitive enhancement and memory support.[1] A New Dietary Ingredient (NDI) notification was filed with the Food and Drug Administration (FDA) as early as 1997.[61] However, its eligibility as a dietary supplement ingredient has been questioned, with some arguing that its highly purified, drug-like nature stretches the definition under DSHEA.[14] The FDA has taken enforcement action against companies making illegal disease-treatment claims for their Huperzine A products, issuing warning letters for marketing it as a treatment for Alzheimer's disease, depression, or other conditions.[14] In a seemingly contradictory move, the FDA has also engaged with Huperzine A as a legitimate investigational drug, granting it an Orphan Drug Designation in 2017 for the treatment of Dravet syndrome, a severe form of epilepsy.[19] This creates a dual identity where it is simultaneously viewed as a potentially illegal supplement and a promising therapeutic agent under formal drug development pathways.
• European Union: In Europe, Huperzine A is not authorized as a medicinal product by the European Medicines Agency (EMA).[65] Furthermore, it is considered a "novel food" under EU regulations, as it does not have a significant history of consumption in the EU before May 1997. This means it cannot be legally marketed as a food or food supplement without undergoing a rigorous pre-market safety assessment and authorization process, which it has not received.[21] The EU's Rapid Alert System for Food and Feed (RASFF) has issued notifications regarding the unauthorized presence of Huperzine A in food supplements imported from the US, classifying the associated risk as "potentially serious".[21]
• Australia: In Australia, Huperzine A is not listed or registered on the Australian Register of Therapeutic Goods (ARTG) by the Therapeutic Goods Administration (TGA).[23] While some supplement products available in Australia may contain it, health authorities have issued warnings cautioning consumers against sourcing products containing Huperzine A from overseas via the internet, citing risks of them being substandard, adulterated, and dangerous.[23]

Formulations, Dosages, and Delivery Systems

The formulation and dosage of Huperzine A have evolved from basic oral forms to more advanced delivery systems designed to optimize its therapeutic index.

• Current Formulations: The most common formulations are oral tablets and capsules, which are used in both clinical trials and commercial supplements.[20] Dosages for these products typically range from 50 micrograms (mcg) to 200 mcg per unit.[15] Intramuscular (IM) injections have also been utilized in clinical research, particularly for conditions like myasthenia gravis.[15]
• Dosage in Clinical Trials: The doses investigated in clinical trials for AD have varied. Earlier studies and those for milder cognitive impairment often used doses of 30-50 mcg twice daily.[15] More recent and robust trials for AD have explored higher doses, typically ranging from 50-200 mcg twice daily, with some Phase II studies testing doses as high as 400 mcg twice daily.[11]
• Emerging Formulations: Recognizing the challenges of frequent dosing (particularly in a dementia population) and the potential for peak-dose-related side effects, significant research has focused on developing novel delivery systems. Controlled-release and sustained-release oral formulations are a key area of development, with patents filed and clinical trials approved in China for biphasic tablets designed for once-daily administration.[18] These advanced formulations aim to provide more stable plasma concentrations over 24 hours, which could potentially enhance efficacy, improve patient compliance, and reduce the incidence of cholinergic side effects.[18] In addition, preclinical research in animal models has explored the feasibility of transdermal patches as an alternative delivery route.[17]

Synthesis and Expert Recommendations

Consolidated Assessment of Therapeutic Potential

Huperzine A presents as a neuropharmacological agent of considerable promise, distinguished by a compelling dual-action profile. Its foundation lies in potent, selective, and reversible acetylcholinesterase inhibition, providing a strong rationale for symptomatic improvement in cholinergic-deficient states like Alzheimer's disease. This is complemented by a rich and varied portfolio of non-cholinergic, neuroprotective mechanisms—including NMDA receptor antagonism, antioxidant activity, anti-inflammatory effects, and favorable modulation of amyloid precursor protein processing—that collectively suggest a potential to modify the underlying course of neurodegeneration. This multifaceted activity, which targets both symptoms and pathology, sets it apart from conventional AChE inhibitors. Its therapeutic appeal is further enhanced by a favorable pharmacokinetic profile characterized by good oral bioavailability, effective blood-brain barrier penetration, and, most notably, a low potential for metabolic drug-drug interactions due to its primary reliance on renal excretion rather than hepatic CYP450 metabolism.

However, this significant therapeutic promise is currently balanced by a clinical evidence base that remains inconclusive. While a large number of trials, primarily from China, and their subsequent meta-analyses consistently point toward benefits in cognition and daily function, this body of work is pervasively marred by significant methodological flaws. Issues of inadequate randomization, poor blinding, small sample sizes, and high risk of bias prevent the drawing of definitive conclusions. The single, more rigorously designed US-based Phase II trial yielded mixed results, failing to meet its primary endpoint. Therefore, Huperzine A currently stands as a molecule whose strong preclinical and mechanistic rationale has yet to be unequivocally validated by high-quality, definitive clinical evidence.

Identification of Critical Research and Clinical Gaps

To bridge the gap between promise and proof, several critical areas of uncertainty must be addressed through focused research.

• Definitive Clinical Efficacy: The most pressing need is for large-scale, long-duration, methodologically sound, multi-center randomized controlled trials. The current reliance on small, often flawed studies is the single greatest barrier to its acceptance as a mainstream therapeutic. Future trials must be designed and conducted according to modern international standards (e.g., ICH-GCP) to provide unambiguous evidence of efficacy and safety, particularly in diverse, well-characterized patient populations outside of China.[11]
• Long-Term Safety: The safety of Huperzine A has only been established in short-term studies, typically lasting six months or less. For a drug intended to treat a chronic, progressive disease like AD, this is a critical deficiency. There is an urgent need for data on the safety, tolerability, and potential for adverse events with chronic, long-term administration.[13]
• Disease-Modifying Potential: While preclinical data strongly suggest disease-modifying effects, this has not been demonstrated in humans. The potential of Huperzine A to alter the trajectory of AD remains a compelling but unproven hypothesis. Future clinical research must move beyond purely symptomatic endpoints and incorporate objective biomarkers of neurodegeneration—such as changes in cerebrospinal fluid (CSF) levels of Aβ and tau, or neuroimaging measures like PET scans for amyloid and tau pathology—to directly assess its impact on the underlying disease process.
• Combination Therapy and Comparative Efficacy: The role of Huperzine A in the current and future landscape of AD treatment is undefined. Its efficacy and safety when used in combination with standard-of-care treatments (e.g., other AChEIs, memantine) or with newer anti-amyloid monoclonal antibodies are unknown. Co-administration with other AChEIs is likely contraindicated due to additive toxicity, but its potential synergistic or additive benefits with other classes of drugs warrants investigation.[13] Furthermore, head-to-head trials against an active comparator, such as donepezil, are needed to establish its relative efficacy and tolerability.

Recommendations for Future Research Directions

Based on the identified gaps, the following research priorities are recommended to clarify the therapeutic role of Huperzine A:

1. Conduct a Pivotal Phase III Trial: A definitive, global, multi-center, randomized, double-blind clinical trial is imperative. This trial should be adequately powered and of sufficient duration (e.g., 18-24 months) to detect clinically meaningful effects. It should ideally include at least three arms: Huperzine A (at an optimized dose, likely 400 µg BID or a controlled-release equivalent), placebo, and an active comparator (e.g., donepezil) to assess both absolute and relative efficacy.
2. Integrate Biomarker Sub-Studies: The pivotal trial design should prospectively include the collection of fluid (CSF, plasma) and imaging (MRI, amyloid-PET, tau-PET) biomarkers at baseline and follow-up. This will be essential for exploring the compound's potential disease-modifying effects and for identifying biological signatures that may predict treatment response.
3. Prioritize Long-Term Safety Assessment: All future efficacy trials must incorporate long-term, open-label extension phases. This is the most practical way to gather the crucial safety and tolerability data required for a drug intended for chronic use.
4. Explore Pharmacogenomics: Investigating the influence of genetic variations (e.g., in APOE, cholinergic system genes) on patient response to Huperzine A could help in identifying subpopulations who are most likely to benefit, paving the way for a personalized medicine approach.

Concluding Remarks

Huperzine A stands at a critical juncture. It is a molecule of natural origin with a sophisticated, multi-target pharmacological profile that is highly relevant to the complex pathology of Alzheimer's disease. Its journey from a traditional herbal remedy to a scientifically scrutinized compound has yielded a wealth of promising preclinical data and encouraging, albeit flawed, clinical signals. The future of Huperzine A as a globally recognized and utilized therapeutic agent is not contingent on further preclinical discovery, but on the commitment to conducting the large-scale, high-quality clinical research necessary to resolve the current state of evidentiary uncertainty. Until such definitive trials are completed, Huperzine A will remain a fascinating compound with significant, but as yet unproven, potential, caught in a complex web of scientific promise, clinical ambiguity, and global regulatory discord.

Works cited

1. Huperzine A | C15H18N2O | CID 854026 - PubChem, accessed October 2, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Huperzine-A
2. Huperzine A: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed October 2, 2025, https://go.drugbank.com/drugs/DB04864
3. pubchem.ncbi.nlm.nih.gov, accessed October 2, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/huperzine%20A#:~:text=It%20is%20a%20sesquiterpene%20alkaloid,a%20huperzine%20A(1%2B).&text=Huperzine%20A%2C%20is%20a%20naturally,of%20the%20firmoss%20Huperzia%20serrata.
4. Huperzine A | C15H18N2O | CID 854026 - PubChem, accessed October 2, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/huperzine%20A
5. (-)-Huperzine A (HupA) | AChR inhibitor | Mechanism | Concentration - Selleck Chemicals, accessed October 2, 2025, https://www.selleckchem.com/products/(-)-Huperzine-A.html
6. The pharmacology and therapeutic potential of (−)-huperzine A - PMC - PubMed Central, accessed October 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4863551/
7. What is the mechanism of Huperzine A? - Patsnap Synapse, accessed October 2, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-huperzine-a
8. Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials - PubMed, accessed October 2, 2025, https://pubmed.ncbi.nlm.nih.gov/24086396/
9. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis - PubMed, accessed October 2, 2025, https://pubmed.ncbi.nlm.nih.gov/19221692/
10. Huperzine A for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials - ResearchGate, accessed October 2, 2025, https://www.researchgate.net/publication/257302282_Huperzine_A_for_Alzheimer's_Disease_A_Systematic_Review_and_Meta-Analysis_of_Randomized_Clinical_Trials
11. A phase II trial of huperzine A in mild to moderate Alzheimer disease - PubMed Central, accessed October 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3269774/
12. The effects of Huperzine A on dementia and mild cognitive impairment: An overview of systematic reviews | Request PDF - ResearchGate, accessed October 2, 2025, https://www.researchgate.net/publication/350873719_The_effects_of_Huperzine_A_on_dementia_and_mild_cognitive_impairment_An_overview_of_systematic_reviews
13. Huperzine A & Your Brain | Cognitive Vitality | Alzheimer's Drug Discovery Foundation, accessed October 2, 2025, https://www.alzdiscovery.org/cognitive-vitality/ratings/huperzine-a
14. Huperzine A: Dietary supplements for brain health, accessed October 2, 2025, https://www.opss.org/article/huperzine-dietary-supplements-brain-health
15. Huperzine A: Health Benefits, Side Effects, Uses, Dose & Precautions - RxList, accessed October 2, 2025, https://www.rxlist.com/supplements/huperzine_a.htm
16. HUPERZINE A: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews - WebMD, accessed October 2, 2025, https://www.webmd.com/vitamins/ai/ingredientmono-764/huperzine-a
17. Huperzine A Uses, Benefits & Dosage - Drugs.com, accessed October 2, 2025, https://www.drugs.com/npp/huperzine-a.html
18. New insights into huperzine A for the treatment of Alzheimer's disease - PubMed Central, accessed October 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4003111/
19. Search Orphan Drug Designations and Approvals - FDA, accessed October 2, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=559916
20. The Science-Backed Benefits of Huperzine A You Should Know - Verywell Health, accessed October 2, 2025, https://www.verywellhealth.com/the-benefits-of-huperzine-a-89464
21. Notification 2023.6353 Novel food - huperzine A in food supplement from United States, accessed October 2, 2025, https://webgate.ec.europa.eu/rasff-window/screen/notification/632755
22. The scoop on brain health dietary supplement products containing huperzine A | Request PDF - ResearchGate, accessed October 2, 2025, https://www.researchgate.net/publication/338882427_The_scoop_on_brain_health_dietary_supplement_products_containing_huperzine_A
23. Caution with complementaries for cognitive impairment - Australian Prescriber, accessed October 2, 2025, https://australianprescriber.tg.org.au/articles/caution-with-complementaries-for-cognitive-impairment.html
24. Huperzine A: A Journey Through Time and Nature - Codeage, accessed October 2, 2025, https://www.codeage.com/blogs/education/huperzine-a-a-journey-through-time-and-nature
25. Huperzine A for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials | PLOS One - Research journals, accessed October 2, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0074916
26. (-)-Huperzine A 102518-79-6 | TCI AMERICA - TCI Chemicals, accessed October 2, 2025, https://www.tcichemicals.com/US/en/p/H1700
27. Huperzine A - Wikipedia, accessed October 2, 2025, https://en.wikipedia.org/wiki/Huperzine_A
28. huperzine A 5,9-methanocycloocta[b]pyridin-2(1H)-one, 5-amino-11-ethylidene-5,6,9,10-tetrahydro-7-methyl-, (5R,9R) - The Good Scents Company, accessed October 2, 2025, http://www.thegoodscentscompany.com/data/rw1658791.html
29. (−)-Huperzine A (Hup A, (−)-Selagine, CAS Number: 102518-79-6) | Cayman Chemical, accessed October 2, 2025, https://www.caymanchem.com/product/14620/minus-huperzine-a
30. Huperzine A | CAS 102518-79-6 | ACH inhibitor - StressMarq Biosciences Inc., accessed October 2, 2025, https://www.stressmarq.com/products/small-molecules/inhibitor/huperzine-a-sih-365/
31. (-)-Huperzine A – Acetylcholinesterase Inhibitor - APExBIO, accessed October 2, 2025, https://www.apexbt.com/huperzine-a.html
32. Huperzine A: Is it an Effective Disease-Modifying Drug for Alzheimer's Disease? - PMC, accessed October 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4137276/
33. Huperzine A regulates amyloid precursor protein processing via protein kinase C and mitogen-activated protein kinase pathways in neuroblastoma SK-N-SH cells over-expressing wild type human amyloid precursor protein 695 - PubMed, accessed October 2, 2025, https://pubmed.ncbi.nlm.nih.gov/17945434/
34. Huperzine A and Its Neuroprotective Molecular Signaling in Alzheimer's Disease - MDPI, accessed October 2, 2025, https://www.mdpi.com/1420-3049/26/21/6531
35. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine - SciSpace, accessed October 2, 2025, https://scispace.com/pdf/progress-in-studies-of-huperzine-a-a-natural-cholinesterase-1ligc2xe78.pdf
36. (PDF) Huperzine A: a natural acetylcholinesterase inhibitor with multifunctional neuroprotective effects - ResearchGate, accessed October 2, 2025, https://www.researchgate.net/publication/394515075_Huperzine_A_a_natural_acetylcholinesterase_inhibitor_with_multifunctional_neuroprotective_effects
37. Huperzine A – Knowledge and References - Taylor & Francis, accessed October 2, 2025, https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Pharmaceutical_medicine/Huperzine_A/
38. A summary of pharmacological mechanisms of huperzine A (HupA) in the... - ResearchGate, accessed October 2, 2025, https://www.researchgate.net/figure/A-summary-of-pharmacological-mechanisms-of-huperzine-A-HupA-in-the-treatment-of_fig1_265393918
39. Pharmacokinetics of huperzine A following oral administration to human volunteers, accessed October 2, 2025, https://www.researchgate.net/publication/5504920_Pharmacokinetics_of_huperzine_A_following_oral_administration_to_human_volunteers
40. Ｐｈａｒｍａｃｏｋｉｎｅｔｉｃｓ ｏｆ ｔａｂｌｅｔ ｈｕｐｅｒｚｉｎｅ Ａ ｉｎ, accessed October 2, 2025, http://cdn.amegroups.cn/journals/aps/files/journals/26/articles/7054/public/7054-PB1-R1.pdf
41. Identification of cytochrome P450 1A2 as enzyme involved in the microsomal metabolism of Huperzine A - PubMed, accessed October 2, 2025, https://pubmed.ncbi.nlm.nih.gov/12586202/
42. Evaluation of the in vitro and in vivo metabolic pathway and cytochrome P450 inhibition/induction profile of Huperzine A - PubMed, accessed October 2, 2025, https://pubmed.ncbi.nlm.nih.gov/27751854/
43. Pharmacokinetics of huperzine A following oral administration to human volunteers, accessed October 2, 2025, https://pubmed.ncbi.nlm.nih.gov/18348466/
44. Research - Shanghai Institute of Materia Medica, accessed October 2, 2025, http://english.simm.cas.cn/re/tra/201808/t20180817_196220.html
45. Huperzine A Completed Phase 2 Trials for Alzheimer's Disease (AD) Treatment - DrugBank, accessed October 2, 2025, https://go.drugbank.com/drugs/DB04864/clinical_trials?conditions=DBCOND0049114&phase=2&purpose=treatment&status=completed
46. Study Details | NCT00083590 | Huperzine A in Alzheimer's Disease - ClinicalTrials.gov, accessed October 2, 2025, https://clinicaltrials.gov/study/NCT00083590
47. Huperzine A Study – ADCS, accessed October 2, 2025, https://www.adcs.org/huperzine-a-study/
48. Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type | ClinicalTrials.gov, accessed October 2, 2025, https://www.clinicaltrials.gov/study/NCT07066826
49. Huperzine A in the Treatment of Alzheimer's Disease and Vascular Dementia: A Meta-Analysis - PMC, accessed October 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3930088/
50. Role of huperzine a in the treatment of Alzheimer's disease - PubMed, accessed October 2, 2025, https://pubmed.ncbi.nlm.nih.gov/19240260/
51. Huperzine A - Alzheimer's Drug Discovery Foundation, accessed October 2, 2025, https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Huperzine-A-Cognitive-Vitality-For-Researchers.pdf
52. Home Remedies: Can huperzine A treat Alzheimer's disease? - Mayo Clinic News Network, accessed October 2, 2025, https://newsnetwork.mayoclinic.org/discussion/home-remedies-can-huperzine-a-treat-alzheimers-disease/
53. Cocaine Abuse Completed Phase 1 Trials for Huperzine A (DB04864) | DrugBank Online, accessed October 2, 2025, https://go.drugbank.com/indications/DBCOND0031129/clinical_trials/DB04864?phase=1&status=completed
54. Safety and Preliminary Efficacy of the Acetylcholinesterase Inhibitor Huperzine A as a Treatment for Cocaine Use Disorder - PMC - PubMed Central, accessed October 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4815469/
55. Effect of Huperzine A on Cognitive Function and Perception of Effort during Exercise: A Randomized Double-Blind Crossover Trial, accessed October 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8439683/
56. What are the side effects of Huperzine A? - Patsnap Synapse, accessed October 2, 2025, https://synapse.patsnap.com/article/what-are-the-side-effects-of-huperzine-a
57. (PDF) The effects of huperzine A on gastrointestinal acetylcholinesterase activity and motility after single and multiple dosing in mice - ResearchGate, accessed October 2, 2025, https://www.researchgate.net/publication/235604167_The_effects_of_huperzine_A_on_gastrointestinal_acetylcholinesterase_activity_and_motility_after_single_and_multiple_dosing_in_mice
58. Indication-specific dosing for Chinese club moss, Huperzine Rx-Brain, HUP, HUP A, Memorall, selagine (huperzine A), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information. - Medscape Reference, accessed October 2, 2025, https://reference.medscape.com/drug/chinese-club-moss-huperzine-rx-brain-huperzinea-344542
59. reference.medscape.com, accessed October 2, 2025, https://reference.medscape.com/drug/chinese-club-moss-huperzine-rx-brain-huperzinea-344542#:~:text=huperzine%20A%20increases%20and%20anticholinergic,Use%20Caution%2FMonitor.&text=huperzine%20A%20increases%20and%20atracurium%20decreases%20cholinergic%20effects%2Ftransmission.
60. The scoop on brain health dietary supplement products containing huperzine A - PubMed, accessed October 2, 2025, https://pubmed.ncbi.nlm.nih.gov/31990212/
61. Huperzine A, an alkaloid compound extracted from the herb Huperzia Serrata from General Nutrition Corporation (“GNC”) on its own behalf and on behalf of Marco Hi Tech JV Ltd. - Regulations.gov, accessed October 2, 2025, https://www.regulations.gov/document/FDA-1997-S-0540-0022
62. .APR 2 7 2015 - Regulations.gov, accessed October 2, 2025, https://downloads.regulations.gov/FDA-2015-S-0023-0041/attachment_1.pdf
63. BrainAlert, LLC - 535653 - 12/14/2017 - FDA, accessed October 2, 2025, https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/brainalert-llc-535653-12142017
64. Unproven Alzheimer's Disease Products - FDA, accessed October 2, 2025, https://www.fda.gov/consumers/health-fraud-scams/unproven-alzheimers-disease-products
65. Huperzine A | MedPath, accessed October 2, 2025, https://trial.medpath.com/drug/6097d1fc698856e2/huperzine-a
66. Huperzine A: Unlocking Brain Potential and Beyond - Mr Supplement, accessed October 2, 2025, https://www.mrsupplement.com.au/huperzine-a
67. Alzheimer's Disease (AD) Unknown Status Phase 2 / 3 Trials for Huperzine A (DB04864), accessed October 2, 2025, https://go.drugbank.com/indications/DBCOND0049114/clinical_trials/DB04864?phase=2%2C3&status=unknown_status
68. CN1208054C - Preparing method for sustained releasing huperzine preparation - Google Patents, accessed October 2, 2025, https://patents.google.com/patent/CN1208054C/en